CytomX develops conditionally activated biologics designed to improve the therapeutic index of cancer treatments, including Probody therapeutics that are activated in the tumor microenvironment. The company pursues both internal development programs and collaborations with larger biopharma partners to advance oncology candidates. Its platform aims to enable targeted delivery of antibodies and reduce off-target toxicities.
In Q1 2026, 6 tracked hedge funds held Cytomx Therapeutics, Inc.. 2 funds initiated new positions. Net institutional flows were positive at $33,980,796.
| # | Fund | Shares | Value | Weight | Change |
|---|---|---|---|---|---|
| 1 | Point72 Asset Management | 7,875,390 | 37.01M | 0.05% | +51.8% |
| 2 | Millennium Management LLC | 3,660,190 | 17.20M | 0.01% | +1163.6% |
| 3 | Seven Grand Managers LLC | 325,000 | 1.53M | 0.10% | NEW |
| 4 | Soleus Capital Management LP | 300,000 | 1.41M | 0.06% | NEW |
| 5 | Hudson Bay Capital Management LP | 80,663 | 379,116 | 0.00% | +58.2% |
| 6 | Nierenberg Investment Management Company Inc | 12,555 | 59,009 | 0.03% | 0.0% |